Tumor antigen presentation via major histocompatibility complex on dendritic cells

Tumor antigen presentation via major histocompatibility complex (MHC) on dendritic cells (DCs) is a critical process in the initiation and regulation of anti-tumor immune responses. Dendritic cells are professional antigen-presenting cells that capture, process, and present tumor-associated antigens to T lymphocytes, thereby orchestrating adaptive immunity against cancer. The efficiency of this process is closely linked to patient outcomes. Therapeutic strategies include ex vivo loading/pulsing of autologous dendritic cells with tumor lysates followed by reinfusion as vaccines.

Dendritic cells capture tumor antigens, process them into peptides, and present them on MHC molecules to activate T cells. This presentation can occur via MHC I (direct and cross-presentation to CD8+ T cells) or MHC II (classical presentation to CD4+ T cells), leading to cytotoxic T lymphocyte (CTL) responses or T helper cell-mediated immunity against the tumor.